EverSource Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

EverSource Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.06K	Sell	161 -286	-64%	-$8.44K	﹤0.01%	3273
2026 Q1	$11.1K	Buy	447 +192	+75%	+$4.57K	﹤0.01%	2861
2025 Q4	$5.95K	Buy	255 +14	+6%	+$312	﹤0.01%	3051
2025 Q3	$4.75K	Sell	241 -808	-77%	-$16.6K	﹤0.01%	3174
2025 Q2	$22.8K	Buy	1,049 +788	+302%	+$18.6K	﹤0.01%	2197
2025 Q1	$6.33K	Buy	261 +162	+164%	+$3.65K	﹤0.01%	2382
2024 Q4	$2.07K	Buy	+99	New	+$2.13K	﹤0.01%	2700
2023 Q2	–	Sell	-18	Closed	-$298	–	2512
2023 Q1	$298	Buy	+18	New	+$297	﹤0.01%	2290

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EverSource Wealth Advisors's CPRX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 64% in Q2 2026, selling an estimated $8.44K and leaving 161 shares worth $5.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3273.

EverSource Wealth Advisors first reported a position in CPRX in Q1 2023 and has held it in 8 quarters since. The position peaked at $22.8K in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

EverSource Wealth Advisors held 161 shares of Catalyst Pharmaceutical worth $5.06K as of Q2 2026.
EverSource Wealth Advisors sold 286 Catalyst Pharmaceutical shares in Q2 2026, an estimated $8.44K.
Catalyst Pharmaceutical made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3273 holding.
EverSource Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q1 2023 and has held it in 8 quarters since.
EverSource Wealth Advisors's Catalyst Pharmaceutical position peaked at $22.8K in Q2 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.